Cytek Biosciences (CTKB) IPO Opens 24% Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Cytek Biosciences Announces Pricing of Its Initial Public Offering
July 22, 2021 10:44 PM EDTFREMONT, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Cytek Biosciences or Cytek) (Nasdaq: CTKB), a leading cell analysis solutions company, announced today the pricing of its initial public offering of an aggregate of 16,749,330 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to Cytek from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $200 million. Cytek is offering 11,764,706 shares of common stock and the selling stockholders named in the prospectus are offering 2,799,929 shares of common stock.... More



